The method of treatment of allergic diseases

 

(57) Abstract:

The invention relates to medicine, in particular to Allergology, to methods for treating allergies. Enter any protivolyamblioznye drugs at usual doses and modes. This method leads to long-term and stable remission with various manifestations of cutaneous, respiratory, digestive and other allergies.

The invention relates to medicine, in particular to Pediatrics, Allergology and gastroenterology.

There is a method of treatment of allergic diseases involving the use of antihistamines in various schemes and combinations with calcium channel blockers fat cells, hormonal therapy, symptomatic (outer, bronchodilatory, adsorbents) [M. D. Mashkovsky, 1990], and also with application of different variants of elimination and desensitization. This method is chosen as a prototype.

The disadvantages of the prototype method are:

1. The treatment method of the prototype is symptomatic; in some cases ineffective, i.e. does not lead to clinical recovery.

2. Another disadvantage is that the use of "ptx2">

The aim of the present invention is to improve the effectiveness of treatment until clinical recovery, lengthening the time of remission and relapse prevention.

This goal is achieved by the fact that in the treatment of allergic diseases, along with the use of pathogenetic and symptomatic funds, regardless of the results of routine laboratory tests (search for eggs of worms and cysts of Giardia in the stool) undergo protivolyamblioznye and antihelminthic therapy until complete disappearance of clinical symptoms worm is a protozoal infection. Special attention should be paid to the presence of bruxism, polydipsia, stabilization of the chair and normalization of liver size. From paraclinical methods indirect sign of readjustment may be the disappearance of eosinophilia. In parallel noted the disappearance of clinical symptoms of Allergy. The method involves the use of any drug, effectively acting on parasites taking into account individual patient characteristics (age, individual tolerability, clinical variant manifestations of the worm is a protozoal infection, and so on). The method also includes the periodic relapse rates on ical observation showed the effectiveness of the proposed method. Under our supervision within 3-5 years were 72 patients aged 6 months to 27 years with different clinical variants of allergies (skin allergies, respiratory allergies, digestive allergies and combinations thereof) after the course of therapy, including the treatment of helminth-protozoal infection in 59 (81.9%) came stable remission; 5 (6,9%) had a single recurrence of the manifestations of allergic disease, 7 (9.7 per cent) repeated relapses that required re-treatment worm-protozoal infection, and only one (1.4 percent) child, there was a transformation of allergic dermatitis in the focal form of atopic dermatitis.

Examples of the method.

Example 1. Snezhana About 12 years. Entered DEEB 18 with a diagnosis of bronchial asthma, paroxysmal period.

Months of age received treatment over the "staphylococcal enterocolitis". 6 months after transfer to artificial feeding was noted moderate manifestations of allergic dermatitis. With 7 years was in the dispensary with a diagnosis of bronchial asthma, moderate severity, atopic dermatitis, food and drug sensitization". For the year was tried is her. Received ketotifen courses, fenkarol. At the age of 8 years in close contact with a cat (long trip in the car with the cat on his lap) began an acute attack of expiratory dyspnea requiring urgent hospitalization. The disease was regarded as bronchial asthma, paroxysmal period. From the digestive system was observed hepatomegaly (3 cm from the edge of the costal arch on medioclavicular line). In the analysis of blood eosinophilia 16. In a single study in fecal Giardia cysts were not found.

Simultaneously with the implementation of urgent measures for the child was appointed as furazolidone (0,05 four times a day) for five days, which helped to reduce the duration of polariscopes period up to 3 days. After discharge, the child received a ten-day course of treatment treatment with trichopol (0,25 twice a day), five days refresher course with trichopol (0,25 twice a day). In the next four years, once a year received anti-relapse treatment trichopol or furazolidone (7-10 days). Asthma attacks were no longer detectable. The forecast is favorable.

Example 2. Paul B., age 9. Were outpatients about rasprostranennoe intussusception, got massive antibiotic therapy (ampioks, chloramphenicol), then at the age of 5 months appeared skin changes such as redness of the cheeks and buttocks, at the age of 9 months redness and weeping in the wrist joint and popliteal fossae. Was observed with a diagnosis of atopic dermatitis, in 3 years was diagnosed with widespread atopic dermatitis. Application tavegila, ketotifen long courses for 3 years, as well as external funds, adsorbents, Spa treatment (three stay in the Crimea for a period of 2 to 3 months) were given a temporary improvement. Cutaneous manifestations were increased in the errors in the diet (chocolate, strawberry, eggs).

In the blood was determined twice eosinophilia (8, 9).

At the age of six he received a ten-day course trykhopol (0,25 twice a day), ten days of anti-ten-day course with trichopol in the same dose. Skin changes disappeared within two weeks and did not appear in the next three years of observation.

Relapse courses were not conducted, as the child was under constant medical supervision and did not detect any symptoms of worm-protozoal infection. Diet rassypanija treatment of allergic diseases leads to the following positive effects:

1. Improving the efficiency of treatment until clinical recovery, lengthening the time of remission and relapse prevention.

2. The impact on one of the main etiological factors of allergic diseases - parasitic-protozoal infection with the use of the entire spectrum of medical treatments worm-protozoal infection.

3. The possibility of application of the method for the treatment of all types of allergies (skin, digestive tract, ENT organs, urinary tract, respiratory, including bronchial asthma).

The method of treatment of allergic diseases through the introduction of drugs, characterized in that use protivolyamblioznye medications.

 

Same patents:
The invention relates to medicine, in particular to Oncology, and concerns the application of the antidepressant amitriptyline as a means of having antiallergic action, for the correction of allergic status in patients with lung cancer

The invention relates to medicine and relates to methods for obtaining protein hydrolysate suppressive regulation of allergic reactions, methods of prevention or treatment of allergies

The invention relates to new ascomycin General formula I, where Y represents a phenylene; Z is selected from carboxyl and physiologically hydrolyzable of oxycarbonyl or alkyl, CNS, alkylamino or dialkylamino bearing from 1 to 4 carboxyl or physiologically hydrolyzable oxycarbonyl group; Q is O or S; R1Is H, alkyl or aryl; R2is hydrogen or hydroxyl; R3is methyl, ethyl, propyl or allyl; R4is hydroxyl or alkoxyl; R5-oxoprop or (H, OH), R6- oxoprop, H, HE H, alkoxyl); n is an integer 1 or 2, in free form or in the form of a pharmaceutically acceptable salt

The invention relates to previously unknown compounds, useful in medical and veterinary practice, to their pharmaceutically acceptable salts and biopremier derivatives, to methods for obtaining data of new compounds, to pharmaceutical compositions containing these new compounds, to a single dosage forms of these compositions and to methods of treating patients using these compositions and dosage forms

The invention relates to medicine, specifically to medicines, exhibiting anti-allergic, anti-asthma and anti-inflammatory effect

The invention relates to the field of medicine and is suitable for the treatment of seasonal and perennial allergic rhinitis, conjunctivitis, hay fever, urticaria, including chronic idiopathic urticaria, angioedema, psevdoallergicakie reactions caused by the release of histamine, itching dermatoses, allergic reactions to insect bites and itching of various etiology

The invention relates to cyclopentapeptide formula (I):

cyclo (A-B-C-E-F-(D)-Ala)

in which A, B, C, E and F, independently of one another, may be the same or different and represent a residue of a natural amino acid except cysteine (Cys) and tryptophan (Trp), and accordingly can be an alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), Proline (Pro), serine (Ser), tryptophan (Thr), tyrosine (Tyr) or valine (Val), as well as their physiologically compatible salts
The invention relates to medicine, in particular to endocrinology and preventive medicine, and for the treatment of iodine deficiency in the body

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to using phenylethenyl- or phenylethynyl-derivatives as antagonists of glutamates receptors. Invention describes using compound of the general formula (I):

wherein each among R1, R2, R3, R4 and R5 means independently of one another hydrogen atom, (C1-C6)-alkyl, -(CH2)n-halogen, (C1-C6)-alkoxy-group, -(CH2)n-NRR', -(CH2)n-N(R)-C(O)-C1-C6)-alkyl, phenyl or pyrrolyl that can be unsubstituted or substituted with one or more (C1-C6)-alkyl; each among R, R' and R'' means independently of one another hydrogen atom or (C1-C6)-alkyl; A means -CH=CH- or C≡C; B means ,, , , or wherein R6 means hydrogen atom, (C1-C)-alkyl, -(CH2)n-C(O)OR, or halogen atom; R7 means hydrogen atom, (C1-C6)-alkyl, -(CH2)n-C(O)OR', halogen atom, nitro-group or oxodiazolyl group that can be unsubstituted or substituted with (C1-C6)-alkyl or cycloalkyl; R8 means hydrogen atom, (C1-C6)-alkyl, -(CH2)n-OH, -(CH2)n-C(O)OR'' or phenyl; R9 means (C1-C6)-alkyl; R10 and R11 mean hydrogen atom; R12 means -(CH2)n-N(R)-C(O)-(C1-C6)-alkyl; R13 means hydrogen atom; each R14, R15, R16 and R17 independently of one another means hydrogen atom or (C1-C6)-alkoxy-group; each R18, R19 and R20 independently of one another means hydrogen atom; R21 means hydrogen atom or (C1-C6)-alkyl; R22 means hydrogen atom, (C1-C6)-alkyl or (C1-C6)-alkyl comprising one or more substitutes chosen from groups hydroxy- or halogen atom; R23 means hydrogen atom, (C1-C6)-alkanoyl or nitro-group; each among R24, R25 and R26 independently of one another means hydrogen atom or (C1-C6)-alkyl; n = 0, 1, 2, 3, 4, 5 or 6; X means -O- or -S-; Y means -CH= or -N=, and its pharmaceutically acceptable salts used in preparing medicinal agents designates for treatment or prophylaxis of disorders mediated by mGluR5-receptors. Also, invention describes compounds of the formula (I-A), compound of the formula (I-B-1) given in the invention description, and a medicinal agent used in treatment or prophylaxis of disorders mediated by mGluR5-receptors.

EFFECT: valuable medicinal properties of compounds.

44 cl, 1 tbl, 44 ex

FIELD: medicine.

SUBSTANCE: method involves producing marrow cell suspension from iliac bone and centrifuging it at 2200 rpm during 30 min. Formed elements of the marrow cell suspension are incubated with chemopreparations in thermostat at 37°C during 30 min. Then, the suspension is intravenously reinfused to patient by dripping, once a week. Plasma is separated and frozen at -40°C. 5 said procedures are administered. Radiation therapy is prescribed when indicated. Marrow cell suspension plasma is defrosted in portions 2 weeks later after having finished radiation therapy. The plasma is intravenously reinfused to patient by dripping, once a week after having been incubated with chemopreparations in thermostat at 37°C during 30 min. 5 like procedures are administered.

EFFECT: enhanced effectiveness in treating the cases of metastases with chemotherapy in high doses; reduced risk of toxic complications.

FIELD: medicine, oncology.

SUBSTANCE: it is necessary to fulfill the puncture of posterior section of iliac ala to sample 150 ml medullary suspension into the vial with 50 ml hemoconservant. The vial's content should be supplemented with 40 mg/sq. m doxorubicin, 600 mg/sq. m cyclophosphan and 1.4 mg/sq.m vincristine. The mixture obtained should be incubated at 37°C for 40 min. Then this mixture should be injected for a patient intravenously by drops. Then it is important to conduct infusion of 375 mg/sq.m dacarbazine on the 1st d of therapy. Since the 1st to the 10th d they prescribe per 40 mg/sq. m prednisolone. On the 8th d of therapy one should intravenously inject 10 mg/sq. m bleomycin. The course should be repeated in 14 d. The innovation enables to apply automyelochemotherapy on the 3d-4th stage of systemic malignant disease as the main type of therapy by preventing the increased rate of aseptic necroses of capuit femoris in this category of patients due to the matched injection scheme.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine.

SUBSTANCE: method involves introducing Sevitin at a dose of 0.3 g 4 times during 30 days after having finished traditional anti-alcohol treatment course.

EFFECT: accelerated metabolism process normalization; eliminated oxidation stress manifestations; reduced primary pathological addiction phenomena manifestation.

4 tbl

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to substituted ω-azolylalkane anilides. Invention describes substituted ω-(1H-azol-1-yl)-N-phenylalkaneamides of the general formula (I): wherein Z and Y mean nitrogen atom of CH-group, or they represent the chain -C-CH=CH-CH=CH-C- simultaneously and forming in common an anellated ring; n means a whole number from 1 to 3; Rm are similar or different and mean hydrogen, halogen atom, alkyl group with number of carbon atoms from 1 to 4, alkoxy group, alkylenedioxy group, benzyloxy group, perfluoroalkyl group with number of carbon atoms from 1 to 4, nitro group, alkoxycarbonyl group, carboxyl group, halogenphenylthio group, halogenbenzoyl group; m means a whole number from 0 to 5, their salts with acids. Also, invention describes methods for synthesis of compounds of the formula (I) and their using as anti-aggregative preparations. Invention provides synthesis of novel compounds possessing the useful biological properties.

EFFECT: valuable properties of compounds, improved method of synthesis.

8 tbl, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to bioorganic chemistry and concerns N-acyl derivatives of aminoacids of the general formula I , where n is 2 or 3, and R is , as well as their pharmaceutically acceptable salts and their application as hypolipidemic preparations. Another subject of invention is pharmaceutical composition containing claimed compounds in pharmaceutically effective quantity and method of treatment of lipidosis, atherosclerosis, cardiac and cerebral ischemia, cardiac infarction, stroke.

EFFECT: obtaining aminoacid derivatives with hypolipidemic effect.

8 cl, 28 tbl, 1 dwg, 22 ex

FIELD: medicine; haematology.

SUBSTANCE: for 24 weeks they use individually selected low-caloric diet calculated in kcal at the formula: for women of 18-30 years old (0.0621 × body weight, kg + 2.0357) × 240. 31 - 60 years old (0.0342 × body weight, kg + 3.5377) × 240, older than 60 years old (0.0377 × body weight, kg + 2.7545) × 240, for men 18-30 years old (0.0630 × body weight, kg + 2.8957) × 240, 31 - 60 years old (0.0484 × body weight, kg + 3.6534) × 240, older than 60 years old (0.0491 × body weight, kg + 2.4587) × 240. Additionally Eprosartan 800 mg once a day and Preductal MB 35 mg twice a day are administered. The method provides potentiation of the diet complex effect and particular drugs from the selected pharmacological groups at empirically specified duration of treatment and as a consequence normalising of thrombocyte hemostasis and decrease of risk of thrombotic complications.

EFFECT: decrease of blood plates activity at methabolic syndrome.

1 ex

FIELD: medicine; cardiovascular surgery.

SUBSTANCE: carry out thoracophrenolumbotomic access to aorta. Then the aorta is pressed above by aneurysms and at bifurcation level. After that puncture the aneurysm and also enter 1000 ml of "Kustodiol" in it as a refrigerant.

EFFECT: increase of efficiency of surgical treatment of thoracoabdominal aortic aneurysms at the expense of maintenance of protection of visceral organs during operative treatment and depression of postoperative acute renal insufficiency.

1 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: there is offered application of glutaric acid derivatives of general formula where R1 = imidazole, indole, R2 = COOH, H, or its pharmaceutically acceptable salt as an antiarrhythmic drug (versions), a medical product, a pharmaceutical composition and method of appropriate prescription. There is presented effectiveness of Nαglutaryl-L-histidine, Nαglutaryl-L-tryptophan in arrhythmia caused by adrenal heart rhythm disorder, in nicotine arrhythmia and acute occlusive myocardium disorder.

EFFECT: effective in arrhythmia.

5 cl, 6 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to novel methods (versions) of producing N-acyl derivatives of amino acids of general formula , where n equals 2 or 3; and R is or their salts, using anhydrides of glutaric or succinic acid.

EFFECT: advantages of the proposed methods lie in simplicity of their realisation, easy extraction of the end product and high output of the end products.

2 cl, 27 tbl, 22 ex

Up!